BridgeMD
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients
EU CTIS ID: 2023-507448-36-00
What this study is testing
"To demonstrate the equivalence in efficacy of SB27 to Keytruda, in terms of objective response rate (ORR) in subjects with metastatic non-squamous non-small cell lung cancer (NSCLC)"
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female ≥ 18 years of age
- Have been diagnosed with stage IV non-squamous NSCLC
- Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
- Agree to use adequate methods of contraception
You likely can't join if
- Unable to take folic acid and vitamin B12 supplementation
- Unable to receive chemotherapy during the study
The study team makes the final eligibility decision.
Where it's taking place
- Turkey
- Philippines
- Bosnia and Herzegovina
- Japan
- Malaysia
- Brazil
- Serbia
- India
- Thailand
- Mexico
- Georgia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Turkey; Philippines; Bosnia and Herzegovina; Japan; Malaysia; Brazil and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.